Skip to main content
. Author manuscript; available in PMC: 2022 Nov 15.
Published in final edited form as: Circulation. 2021 Sep 27;144(19):1553–1566. doi: 10.1161/CIRCULATIONAHA.121.055112

Figure 2: Long-term survival curves according to the presence of cardiomyopathy and T.cruzi seropositivity.

Figure 2:

The greatest mortality was found among patients with established cardiomyopathy at baseline, with a mortality rate of 80.9 deaths/1000 person-years follow-up (red line). The mortality rate among T. cruzi–seropositive blood donors without cardiomyopathy at baseline and T. cruzi–seronegative blood donors was similar (light green and dark blue lines are overlapping).

CM = Cardiomyopathy